TherapeuticsMD, Inc. (TXMD)

Market Cap	23.84M +93.8%
Revenue (ttm)	3.27M +27.8%
Net Income	-217,000
EPS	-0.02
Shares Out	11.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,051
Open	2.000
Previous Close	2.010
Day's Range	1.990 - 2.060
52-Week Range	1.030 - 2.950
Beta	0.65
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 1
• Stock Exchange: Nasdaq
• Ticker Symbol: TXMD
• Website: https://www.therapeuticsmd.com

Financial Performance

In 2025, TherapeuticsMD's revenue was $3.02 million, an increase of 71.61% compared to the previous year's $1.76 million. Losses were -$569,000, -73.91% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error